Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Beyond Fat Loss: Addressing the Sarcopenia Challenge of Incretin-Based Therapies
Diabetes & metabolism journal, 2026;50(5):844-862
Precision Medicine in Overlap Syndrome (COPD-Obstructive Sleep Apnea): From Phenotypes and Endotypes to Treatable Traits
Advances in respiratory medicine, 2026;94(5)
GLP-1 receptor agonists in elective spine surgery: a systematic review of fusion outcomes, perioperative safety, and procedure-specific risk
North American Spine Society journal, 2026;28:100942
Perspectives on Newer Antiobesity Drugs (Semaglutide and Tirzepatide) among Healthcare Professionals Treating Obesity in South Asia: A Cross-sectional Survey
The Journal of the Association of Physicians of India, 2026;74(9):67-70
Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension Study
Diabetes, obesity & metabolism, 2026
Association of tirzepatide with changes in OSA-related measures based on baseline characteristics – post hoc analyses of SURMOUNT-OSA
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2026;22(1)
Comment on “Effect of Semaglutide with Metformin for Weight Loss and Fertility in Polycystic Ovary Syndrome (PCOS) Patients with Obesity: A Pilot Prospective Study”
Clinical nutrition ESPEN, 2026;:105077
Reply – Letter to the Editor: Comment on “Effect of Semaglutide with Metformin for Weight Loss and Fertility in Polycystic Ovary Syndrome (PCOS) Patients with Obesity: A Pilot Prospective Study
Clinical nutrition ESPEN, 2026;:105080
Metabolic Dysfunction-Associated Steatotic Liver Disease: Current Treatment Strategies and Novel Therapies
Gut and liver, 2026
Tirzepatide non-response with subsequent semaglutide response in class 2 obesity
JCEM case reports, 2026;4(9):luag245
A new era in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): clinical breakthroughs and challenges
Frontiers in pharmacology, 2026;17:1815576
Glucagon-like peptide-1 receptor agonists and tirzepatide are associated with reduced mortality, cardiovascular, and psychiatric risks in patients with hidradenitis suppurativa and type 2 diabetes and/or obesity: a retrospective cohort study
Frontiers in medicine, 2026;13:1909537
Neuropsychiatric Outcomes Associated with GLP-1 Receptor Agonists in Adults with Overweight or Obesity: A Systematic Review
Brain sciences, 2026;16(9)
Potential Role of the Triple Receptor Agonist Retatrutide in Antipsychotic-Associated Metabolic Dysfunction Among Clozapine- and Olanzapine-Treated Schizophrenia Spectrum Disorders: A Narrative Review and Theoretical Framework
Biomedicines, 2026;14(9)
Comparison of cardiometabolic benefits and tolerability in patients on sustained low doses of semaglutide or tirzepatide
Biology methods & protocols, 2026;11(1):bpag048
Intrathecal semaglutide attenuates burn injury-induced pain in mice through a spinal GLP-1R-linked enkephalin/δ-opioid receptor pathway
Neuropharmacology, 2026;:111163
Intranasal delivery of Semaglutide using a thermoresponsive PNPHO nanocarrier: formulation development, characterization and biological evaluation
International journal of pharmaceutics, 2026;:127363
Unilateral Graves’ Disease Developing During Treatment With Tirzepatide in a Patient With Diabetes: A Case Report
Case reports in endocrinology, 2026;2026:9628050
Beyond Weight Loss: Thromboinflammation as a Candidate Mechanism for the Cardiovascular Benefit of GLP-1 Receptor Agonists
Cells, 2026;15(17)
Efficient Expression of Small Molecule Bioactive Peptides in Bacillus licheniformis
Applied biochemistry and biotechnology, 2026